MAP3K8
Reaktivität: Human, Ratte, Maus
WB, ELISA, IHC (p), IF (cc), IF (p), IHC (fro), FACS
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
MAP3K8
(Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))
COT, a member of the MAPKKK subfamily of Ser/Thr protein kinases, is able to activate NF-kappa-B 1 by stimulating proteasome-mediated proteolysis of NF-kappa-B 1/p105. It plays a role in the cell cycle. The longer form of cot has some transforming activity, although it is much weaker than the activated cot oncoprotein. This cytoplasmic protein is expressed in several normal tissues and human tumor-derived cell lines. The 58 kDa form is activated specifically during the S and G2/M phases of the cell cycle. The longer form undergoes phosphorylation on Ser residues mainly, and the shorter form on both Ser and Thr residues.Synonyms: COT, COT proto-oncogene serine/threonine-protein kinase, Cancer Osaka thyroid oncogene, ESTF, MAPK, Mitogen-activated protein kinase kinase kinase 8, Tumor progression locus 2, Tumor progression locus 2